• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Benitec Biopharma Inc.

    4/29/24 11:44:13 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNTC alert in real time by email
    SC 13G 1 tm2412949d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

     

    Benitec Biopharma Inc.
    (Name of Issuer)

     

    Common Stock, $0.0001 par value
    (Title of Class of Securities)

     

    08205P100
    (CUSIP Number)

     

               April 22, 2024           
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1 (b)

     

      x Rule 13d-1 (c)

     

      ¨ Rule 13d-1 (d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s))
    Page 1 of 7 Pages

     

     

     

     

     

    CUSIP No. 08205P100 13G Page 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON
    Nemean Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    -0-

     

    6

    SHARED VOTING POWER
    746,324

     

    7

    SOLE DISPOSITIVE POWER
    -0-

     

    8

    SHARED DISPOSITIVE POWER
    746,324

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    746,324

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    8.39%

     

    12

    TYPE OF REPORTING PERSON
    CO

     

                           

     

     

     

     

    CUSIP No. 08205P100 13G Page 3 of 7 Pages

      

    1

    NAME OF REPORTING PERSON
    IRA financial trust FBO Steven M. Oliveira Roth IRA

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    0

     

    6

    SHARED VOTING POWER
    44,911

     

    7

    SOLE DISPOSITIVE POWER
    0

     

    8

    SHARED DISPOSITIVE POWER
    44,911

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    44,911

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0.01%

     

    12

    TYPE OF REPORTING PERSON
    OO

     

                           

     

     

     

     

    CUSIP No. 08205P100 13G Page 4 of 7 Pages

     

    1

    NAME OF REPORTING PERSON
    Steven M. Oliveira

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.A.

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    0

     

    6

    SHARED VOTING POWER
    791,235

     

    7

    SOLE DISPOSITIVE POWER
    0

     

    8

    SHARED DISPOSITIVE POWER
    791,235

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    791,235

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    8.89%

     

    12

    TYPE OF REPORTING PERSON
    IN

     

                           

     

     

     

     

    CUSIP No. 08205P100 13G Page 5 of 7 Pages

     

    Item 1.

     

      (a) Name of Issuer: Benitec Biopharma Inc. (the "Company").

     

      (b) Address of Issuer's Principal Executive Offices:

     

    The Company's principal executive offices are located at 3940 Trust Way, Hayward, CA 94545.

     

    Item 2.

     

      (a) Name of Person Filing: Nemean Asset Management, LLC
          IRA financial trust FBO Steven M. Oliveira Roth IRA
          Steven Oliveira

     

      (b) Address of Principal Business Office or if none, Residence:

     

    Nemean Asset Management, LLC:

     207 Commodore Drive

    Jupiter, FL 33477

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA:

    c/o Nemean Asset Management, LLC

    207 Commodore Drive

    Jupiter, FL 33477

     

    Steven Oliveira:

    c/o Nemean Asset Management, LLC

    207 Commodore Drive

    Jupiter, FL 33477

     

      (c) Citizenship: Nemean Asset Management, LLC – Florida

    IRA financial trust FBO Steven M. Oliveira Roth IRA: - U.S.A.

    Steven Oliveira – U.S.A.

     

      (d) Title of Class of Securities:  Common Stock, $0.0001 par value

     

      (e) CUSIP Number:  08205P100

     

    Item 3. Not Applicable

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount Beneficially Owned:

     

    Nemean Asset Management, LLC – 746,324

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 44,911

     

    Steven Oliveira – 791,235.

     

    Steven Oliveira has voting and dispositive power over the securities owned by Nemean Asset Management, LLC and the Roth IRA.

     

     

     

     

    CUSIP No. 08205P100 13G Page 6 of 7 Pages

     

      (b) Percent of Class:

     

    Nemean Asset Management, LLC – 8.39%

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 0.01%

     

    Steven Oliveira – 8.89%

     

    The foregoing percentages are based upon a total of 8,898,946 shares of Common Stock.

     

     

      (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote:

     

    Nemean Asset Management, LLC – 0.

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA - 0

     

    Steven Oliveira – 0

     

      (ii) shared power to vote or to direct the vote:

     

    Nemean Asset Management, LLC – 746,324

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 44,911

     

    Steven Oliveira – 791,235

     

      (iii) sole power to dispose or to direct the disposition of:

     

    Nemean Asset Management, LLC – 0.

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA - 0

     

    Steven Oliveira – 0

     

      (iv) shared power to dispose or to direct the disposition of:

     

    Nemean Asset Management, LLC – 746,324

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 44,911

     

    Steven Oliveira – 791,235

     

    Item 5. Ownership of Five Percent or Less of a Class: No

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable

     

    Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: Not Applicable

     

    Item 8. Identification and Classification of Members of the Group: Not Applicable

     

    Item 9. Notice of Dissolution of Group: Not Applicable

     

    Item 10. Certifications: Not Applicable

     

     

     

     

    CUSIP No. 08205P100 13G Page 7 of 7 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    April 29, 2024

     

      NEMEAN ASSET MANAGEMENT, LLC
         
      By: /s/ Steven Oliveira
        Name: Steven Oliveira
        Title: Authorized Signatory
         
      IRA FINANCIAL TRUST FBO STEVEN M. OLIVEIRA ROTH IRA
         
        /s/ Steven Oliveira
         
      STEVEN M. OLIVEIRA
       
        /s/ Steven Oliveira
        Steven Oliveira

     

     

     

    Get the next $BNTC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BNTC

    DatePrice TargetRatingAnalyst
    7/7/2025Buy
    TD Cowen
    12/16/2024$28.00Buy
    H.C. Wainwright
    12/13/2024$30.00Outperform
    Robert W. Baird
    10/16/2024$35.00Outperform
    Oppenheimer
    9/12/2024$17.00Buy
    Guggenheim
    7/22/2024$13.00Outperform
    Leerink Partners
    6/13/2024$30.00Overweight
    Piper Sandler
    2/17/2022$10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BNTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Benitec Biopharma Provides Operational Updates

      -In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring Board Review Has Been Completed for All Six Subjects Enrolled into Cohort 1, and the Data Safety Monitoring Board Recommended Continuation of Subject Enrollment for the Phase 1b/2a Clinical Treatment Study- -Following the Positive Data Safety Monitoring Board Recommendation, Enrollment of Cohort 2 is Expected to Begin in Q4 2025- HAYWARD, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnolo

      7/9/25 8:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Releases Third Quarter 2025 Financial Results

      HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its third fiscal quarter ended March 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission. "We are profoundly honored to be closely engaged with the OPMD patient community and are thankful for the support of the Subjects and their families as we remain focused on the continued development

      5/14/25 7:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

      HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital. Each share of common stock is being sold at an offering price of $13.00 and each pre-funded warra

      3/25/25 8:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Suvretta Capital Management, Llc bought $211,736 worth of shares (16,497 units at $12.83) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      4/2/25 4:37:02 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $11,700,000 worth of shares (900,000 units at $13.00) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/28/25 4:51:41 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Buchi J Kevin gifted 103,626 shares and received a gift of 103,626 shares, decreasing direct ownership by 100% to 284 units (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/13/25 4:43:09 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Benitec Biopharma

      TD Cowen initiated coverage of Benitec Biopharma with a rating of Buy

      7/7/25 8:17:08 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Benitec Biopharma with a new price target

      H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00

      12/16/24 6:46:22 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Benitec Biopharma with a new price target

      Robert W. Baird initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $30.00

      12/13/24 7:25:56 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    SEC Filings

    See more
    • Benitec Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Benitec Biopharma Inc. (0001808898) (Filer)

      7/9/25 4:16:53 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Benitec Biopharma Inc.

      EFFECT - Benitec Biopharma Inc. (0001808898) (Filer)

      6/3/25 12:15:09 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Benitec Biopharma Inc.

      424B3 - Benitec Biopharma Inc. (0001808898) (Filer)

      6/2/25 5:04:46 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Suvretta Capital Management, Llc bought $211,736 worth of shares (16,497 units at $12.83) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      4/2/25 4:37:02 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $11,700,000 worth of shares (900,000 units at $13.00) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/28/25 4:51:41 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $527,174 worth of shares (47,520 units at $11.09) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      12/26/24 4:28:03 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Financials

    Live finance-specific insights

    See more
    • Benitec Biopharma Releases Third Quarter 2025 Financial Results

      HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its third fiscal quarter ended March 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission. "We are profoundly honored to be closely engaged with the OPMD patient community and are thankful for the support of the Subjects and their families as we remain focused on the continued development

      5/14/25 7:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

      -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024. The Company has filed its

      2/14/25 8:10:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

      -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society- -Third Subject Safely Treated with the Low-Dose of BB-301 in October 2024, and Fourth Subject Expected to Receive Treatment with the Low-Dose of BB-301 in December 2024 HAYWARD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing no

      11/14/24 4:30:00 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

      HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

      7/1/24 7:00:00 AM ET
      $BHVN
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

      SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      12/6/24 1:47:28 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

      SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

      11/18/24 4:36:00 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

      SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      11/14/24 1:37:20 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care